Swisscom, Ericsson and the École Polytechnique Fédérale de Lausanne (EPFL) initiated the “5G for Switzerland” programme in the summer of 2016 in order to carry out joint research in this new mobile telephony standard. Swisscom seeks to offer its customers the best infrastructure. Swisscom is working intensively on the development of 5G in order to make this latest technology available to its customers as early as possible. 5G will enable greater speed, greater capacities and shorter reaction times. The economy, science, industry as well as residential customers will benefit from it in equal measure. Digitisation is also being worked on in the direction of Industry 4.0. In addition, Swisscom is promoting the further development of 4G and now provides 4G+ with speeds of up to 300 Mbit/s to 40% of the population; at the end of the year, it will be 67%. Swisscom already covers 15% of the population with speeds of up to 450 Mbit/s.
Ypsomed is the leading developer and manufacturer of injection and infusion systems for selfmedication and a renowned diabetes specialist with 30 years experience. As an innovation and technology leader, the company is the preferred partner of pharmaceutical and biotech companies for pens, auto-injectors and pump systems for administrating liquid medication. Ypsomed presents and distributes its product portfolios under the umbrella brand mylife Diabetescare directly to patients or via pharmacies and clinics, as well as under YDS Ypsomed Delivery Systems in business-to-business operations to pharmaceutical companies. The company is based in Burgdorf, Switzerland, and has a global network of production sites, subsidiaries and sales partners employing around 1300 staff worldwide
“It is of great value to us that we can attract Ypsomed as our first industrial partner for our "5G for Switzerland" programme. This will enable us to gain key insights into the digitisation of industry processes.” says Heinz Herren, CTO and CIO of Swisscom. 5G-specific features, such as extremely high bandwidths and long latency periods, are being tested. But they are also investigating aspects of wirelessly-networked production and its integrated data processing. Here, technology such as edge computing is being used for the first time. The cloud will become an integral component of a base station and control IT production processes both locally and directly. Ypsomed aims to gain experience of 5G technology early on in order to prepare for the new age of mobile-networked production. Ypsomed also aims to be able to benefit quickly from the economies of scale in production IT. “At Ypsomed, we are investing a lot in the digitisation of the injection systems and we see some great opportunities for growth. We want to fully exploit the potential for digitisation and apply it to all processes,” explains Ypsomed CEO Simon Michel about their collaboration with Swisscom.
Press Release
Swisscom 5G
Related Posts:
Ypsomed is the leading developer and manufacturer of injection and infusion systems for selfmedication and a renowned diabetes specialist with 30 years experience. As an innovation and technology leader, the company is the preferred partner of pharmaceutical and biotech companies for pens, auto-injectors and pump systems for administrating liquid medication. Ypsomed presents and distributes its product portfolios under the umbrella brand mylife Diabetescare directly to patients or via pharmacies and clinics, as well as under YDS Ypsomed Delivery Systems in business-to-business operations to pharmaceutical companies. The company is based in Burgdorf, Switzerland, and has a global network of production sites, subsidiaries and sales partners employing around 1300 staff worldwide
Press Release
Swisscom 5G
Related Posts:
No comments:
Post a Comment